Emilia Louisa Ernestine Schäfer

Mrs. Emilia Louisa Ernestine Schäfer

OncoRay, Dresden, Saxony, Germany
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MFMiriam Frenken
Miriam Frenken
KRKarl Ludger Radke
Karl Ludger Radke
ESEmilia Louisa Ernestine Schäfer
Emilia Louisa Ernestine Schäfer
BVBirte Valentin
Birte Valentin
LWLena Wilms
Lena Wilms
AMAnja Müller-Lutz
Anja Müller-Lutz
(1) Background: We aim to investigate age-related changes in cartilage structure and composition in the metacarpophalangeal (MCP) joints using magnetic resonance (MR) biomarkers. (2) Methods: The cartilage tissue of 90 MCP joints from 30 volunteers without any signs of destruction or inflammation was examined using T1, T2, and T1ρ compositional MR imaging techniques on a 3 Tesla clinical scanner and correlated with age. (3) Results: The T1ρ and T2 relaxation times showed a significant correlation with age (T1ρ: Kendall-τ-b = 0.3, p < 0.001; T2: Kendall-τ-b = 0.2, p = 0.01). No significant correlation was observed for T1 as a function of age (T1: Kendall-τ-b = 0.12, p = 0.13). (4) Conclusions: Our data show an increase in T1ρ and T2 relaxation times with age. We hypothesize that this increase is due to age-related changes in cartilage structure and composition. In future examinations of cartilage using compositional MRI, especially T1ρ and T2 techniques, e.g., in patients with osteoarthritis or rheumatoid arthritis, the age of the patients should be taken into account.

7 October 2026 in Physics in Medicine & Biology
Verified
Journal Article
Open access
MCMarisa Cobanaj
Marisa Cobanaj
FLFranciska Lebbink
Franciska Lebbink
SSSergej Schneider
Sergej Schneider
ESEmilia Louisa Ernestine Schäfer
Emilia Louisa Ernestine Schäfer
KPKrishna Godino Padre
Krishna Godino Padre
FHFelix Horst
Felix Horst
Objective. Integrating in-beam magnetic resonance imaging (MRI) with proton therapy (PT) introduces magnetic fields (MFs) that affect proton beam transport and therefore require accurate incorporation into the treatment planning system (TPS) for magnetic resonance (MR)-integrated PT (MRiPT). This study experimentally validates Monte Carlo-based proton dose calculation in the presence of the MF in a research version of the commercial TPS RayStation for MRiPT, using a measured three-dimensional (3D) magnetic vector field map of a 0.32 T in-beam MR scanner combined with a horizontal proton pencil beam scanning beam line. Approach. An MR-compatible mapping framework was used to acquire a high-resolution 3D magnetic vector field map, subsequently implemented into the TPS following coordinate transformations. Proton spot patterns and square radiation fields at 100, 150, and 220 MeV were delivered with and without the MF present. Dose distributions in air were measured using a 2D ionisation chamber array at multiple positions and compared with TPS dose calculations by analysing lateral beam shifts and field shape deformations with local γ -analysis. Clinically relevant patient treatment fields were evaluated at different water-equivalent depths (WEDs) in a phantom. Main results. Implementation of the measured magnetic vector field map preserved field vector magnitude, orientation and spatial alignment within the TPS. Dose measurements showed energy- and position-dependent MF-induced effects, which were accurately reproduced by the TPS. Agreement in lateral beam shifts was within 1–3 mm, and γ -pass rates exceeded 97% for a 3%/3 mm local criterion (10% dose threshold). Similar agreement was observed for patient treatment fields throughout all WEDs. Significance. This work validates the TPS capability to accurately model MF-induced proton beam transport in air as well as in a water-equivalent phantom. The present workflow establishes a foundation for proton treatment planning in the presence of MFs and thereby contributes to the clinical implementation of MRiPT.